% | $
Quotes you view appear here for quick access.

ImmunoGen, Inc. Message Board

johngunn51 41 posts  |  Last Activity: Oct 2, 2015 12:07 PM Member since: Mar 8, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    Ward Killed the Company

    by wayne21044 Oct 2, 2015 11:44 AM
    johngunn51 johngunn51 Oct 2, 2015 12:07 PM Flag

    Outside of the fact that they hired a woman CEO, they're just not creative, forward thinking or quick. Right after they bought vessels the market for ethanol tanks boomed, and they missed it. Then it boomed for CNG and propane and they missed it. They totally missed the boom in bio-containment facilities with Scientific. They buy boring businesses and make them more boring. IMO they shouldn't be a public company. Randy got on the call yesterday- he is usually the only caller and complained about pretty much everything and then lost all credibility when he said he would buy more stock. Seems like he's a glutton for punishment. I'm done with this happy horseshit.

  • Small companies should be nimble. Should be able to forecast downturns. Not here. Should be able to identify emerging market opportunities. Not here. They get a D-, Stock headed to 2's IMO. I'm very disappointed. Sold off a substantial portion of my position this morning. Tax losses were not what I was lookin' for.

  • Reply to


    by johngunn51 Sep 19, 2015 12:39 PM
    johngunn51 johngunn51 Sep 24, 2015 11:54 AM Flag

    My info is from Rennaissance Capital. Set for 4.65 mil shares at 13-15 per. Market cap post IPO would be around 225 mil. The exact day and terms are subject to determination the night before the sale. Usually, if the market is in panic selling mode, they delay it. Another RNAI firm Arrowhead reported positive clinical trial data this morning on a Hep B treatment and shot up 20% even in a horrible market.

  • 300 747's both body types.. Order from China followed Xiao Jai Ping visit to Seattle.

  • The Wainright registered direct " customers" didn't just show up Friday afternoon. They were in on the deal from the beginning. Company releases "Fast Track Designation" press release Friday morning. Private" investors" in on the deal shorted the stock Friday afternoon at 5.00-7.50. The "offering" was announced on the weekend, and tomorrow the "investors" will use the stock they knew they were buying for 4.35 to cover the short and make a fast 50% mostly taken from the pockets of the unfortunate neophytes who bought Friday afternoon. And they get the warrants for free, just in case the 3% chance that the drug is approved sometime before 2020 pans out.

  • Reply to

    Trades around 4.00 4.50 tomorrow

    by johngunn51 Sep 20, 2015 6:51 PM
    johngunn51 johngunn51 Sep 20, 2015 7:52 PM Flag

    I'm not short, I have a friend who passed away Sept. 1 of liver cancer after taking Nexavar so I follow this stuff. This is at best a second line- adjunctive treatment. And Phase 2 enrollment will not be completed until at least July 2016 with preliminary, partial results not reported until at least Feb. 2017 even w Fast Track. This is a 25mg oral pill taken twice daily, And it's going to prevent liver failure? Are you kidding me?

  • That's my guess. You have to figure the warrants are worth .75-1.25 so deduct that from the offering price, and that's what the accredited invstors paid. I've been burned on 2 previous Israeli "clinical" stage biotechs- ADHD and BioLine. Both announced "encouraging" results in Phase2 trials and orphan drug designations, which are easy to get and mean nothing.The stocks popped, then they raised money w registered direct offerings. Phase 3 bombed, stocks tanked. Caveat emptor..

  • The symbol will be MIRN. With DNAI and MIRN both public, it's just a matter of time for Marina to take off. I would double down on all positions next week. Major upside, IMO

  • johngunn51 johngunn51 Sep 9, 2015 7:39 PM Flag

    In my experience, which is extensive, technicals and charts are pretty much unpredictive on micro-caps. The Eyegate float is

  • My guess is 17-20 and within 12 months. Six days ago Allergan acquired pre IPO AqueSys for 300 mil cash plus milestones for a minimally invasive glaucoma stent .The thinking there was the longer they waited the higher the price. There really has been no new technology in eye surgery in 100 years and the space is now getting major attention. My guess is Valeant, but could be J&J or Allergan just as easily. Right now good time to buy IMO. Post IPO quiet period over and analyst recommendation from Aegis with double digit target probably about to be released.

  • Everybody knows by now, Buffet just paid 37Bil for Precision Castparts. Lesser known but perhaps equally indicative of the surging interest in the sector, is Liberty Hall, which bought up Accurus Aerospace recently, and Primus and Firth Rixson previously. When the new plant is up and running IKNX is a 50-100 stock IMO. Now is the best time to buy it.

  • johngunn51 johngunn51 Aug 28, 2015 2:46 PM Flag

    Well let's see. Up everday for 10 days since you sold. $1.05 at the moment. You missed the insider buying. Don't miss the board member announcement next week, don't miss the technology deal in September, and don't miss the Adage investment or the Baker Bros investments after that.

  • Reply to

    Nasdaq top 10 gainers list 2 days in a row?

    by johngunn51 Aug 21, 2015 3:56 PM
    johngunn51 johngunn51 Aug 21, 2015 4:52 PM Flag

    You know just enough to be dangerous. Trading algos do not go long on disconnected junk stocks during hard market corrections. The HF props are high volume symbols that are liquid and where a penny can be buried and resurrected in 5 minutes without distorting the market. If they are long anything it's vulture and mercenary material like VIX options and haven options like gold and treasuries. I worked on the street for 15 years and retired wealthy- gimme a little credit

  • Rarely happens. There are prop traders out there who automatically short them after the first day on the list, so they go down the next. HART is not readily shortable so we are seeing nothing but pure unadulterated conviction buying ahead of the new director appointment. Pretty freakin' cool!

  • Stop/losses, margin calls, tax loss captures, index tracking trades and fear have made this the buy of the decade. Right here, right now, load up and go enjoy the day... Double plus from here in Spring.

  • He has lined his pockets every year for the past 6 with secondaries, litigation awards, non-performance awards, and obscene option grants. I have all his calls and interviews on tape. In the beginning it was bootstrap, organic growth, thin film on silicon, acquisitions using stock. Now it's a straight stock offering w another $.5mil to go to selling insiders. Why can't Avi use stock to make acquisitions? Duh, cause no one w half a brain and the ability to read a financial statement wants it. The offering will be at a discount to the close. Sell first thing in the morning. The guys's a shmuck, what part of no one gets rich on Gigoptix but him don't you get.

  • Reply to

    In defense of McGorry

    by johngunn51 Aug 19, 2015 7:51 PM
    johngunn51 johngunn51 Aug 20, 2015 11:37 AM Flag

    I remember 2 yrs ago buying ADXS at 2.30 when a VP from ImClone took over a struggling immunotherapy company w failed trials that had been banished to the pink sheets.. The market cap was about the same as HART"s is now. It is now about .5Bil. He did this by leveraging IP knowledge and human resources gained from his experience at ImClone. He recently hired the global head of oncology product development from Merck among others, a brilliant man who is quite excited for the blue sky opp. For a lot of these folks working at the Merck's, the Roche's, and the Novartis's is boring and lacking in challenge and opportunity. Judging from how he came across on the CC and his public statements, McGorry believes he has moved up not down in taking the CEO job at HART.. I don't care about last year's trachea transplant. We're at ground zero here at 10mil cap w McGorry and lots of blue sky.

  • johngunn51 by johngunn51 Aug 19, 2015 7:51 PM Flag

    He worked at Genzyme for 12 years, ending as international VP of development. Maybe some of you forgot or never knew but Genzyme was the third largest biotech in the world by market cap when they were bought by Sanofi Aventis in 2010- their annual revenues increased from 130 mil to almost 4 bil while McGorry worked there. If you want to hold it against him that he graduated with honors from West Point got his MBA at Fuqua, was a special forces dive captain, but doesn't have an M.D. or phD after his name then perhaps all the money you lost buying this stock at the wrong price made you bitter. I didn't buy it until the last few days. It looks very interesting to me here.

  • Reply to

    Fire in the Hole!

    by johngunn51 Aug 18, 2015 10:04 PM
    johngunn51 johngunn51 Aug 19, 2015 7:24 PM Flag

    Tequila and Qualudes available now and ecstasy as well. Spana has spent almost his entire adult life trying to invent a pill to make women #$%$. With other people's money no less. What kinda degenerate does that? If I ran the SEC I would try to see to it he shares a cell with Jared Fogle.

  • Reply to

    Diminishing losses, returns

    by te_st_5674 Aug 19, 2015 1:51 PM
    johngunn51 johngunn51 Aug 19, 2015 2:21 PM Flag

    You can't look at it like that- cost basis of 6 bucks, now worth .60. You have to look at it at in freeze frame at .60. A regenerative medicine science company in Boston selling below cash value w a great new CEO and a new director- not Langer but a respected RM name to be introduced within the next couple of weeks. This stock could run fast and far from here. Sure it's speculative but at the present price it's very compelling.

10.61-0.36(-3.28%)2:40 PMEDT